Chromadex (CDXC) Receiving Somewhat Favorable Press Coverage, Analysis Shows

News coverage about Chromadex (NASDAQ:CDXC) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chromadex earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.95213284946 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

A number of equities research analysts recently weighed in on the company. BidaskClub cut Chromadex from a “strong-buy” rating to a “buy” rating in a report on Friday. Ladenburg Thalmann Financial Services assumed coverage on Chromadex in a report on Monday, September 25th. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research raised Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a report on Tuesday, November 28th. HC Wainwright raised their price target on Chromadex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 27th. Finally, ValuEngine cut Chromadex from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $7.13.

Shares of Chromadex (NASDAQ CDXC) opened at $6.02 on Friday. The company has a market capitalization of $336.48, a price-to-earnings ratio of -43.00 and a beta of 1.38. Chromadex has a 52 week low of $2.26 and a 52 week high of $7.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 4.12.

In other news, major shareholder River Ventures Ltd Champion bought 731,707 shares of the stock in a transaction dated Friday, November 17th. The stock was bought at an average cost of $4.10 per share, with a total value of $2,999,998.70. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.59% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Chromadex (CDXC) Receiving Somewhat Favorable Press Coverage, Analysis Shows” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at

Chromadex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

What are top analysts saying about Chromadex? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chromadex and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit